22 results about "Biogenesis" patented technology

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

The invention belongs to the field of biological medicine, and relates to application of triptolide in preparation of a medicine for preventing and treating calcified aortic valve diseases. The triptolide is found to be capable of promoting expression and maturation of CTSD and activating enzyme activity of the CTSD, meanwhile, biogenesis of lysosome in valvular interstitial cells can be promoted by regulating and controlling AKT / mTOR / TFEB signal axes, lysosome functions are improved, autophagy flux is recovered, and finally the effect of treating the calcified aortic valve disease is achieved. A novel treatment medicine is provided for the calcified aortic valve disease.

A biological nanoparticle for targeted therapeutic delivery is provided. The biological nanoparticle includes a plurality of extracellular vesicles. Characteristically, each extracellular vesicle contains a microRNA, which has been modified with ExoMotif sequences to enhance selective loading into the vesicles during their biogenesis. The microRNA is configured to inhibit plaque formation and vascular calcification. Additionally, a hydroxyapatite-binding peptide (HABP) is conjugated to the surface of each extracellular vesicle, facilitating targeted delivery to calcified tissues. This configuration enables the nanoparticle to specifically target areas of vascular calcification, where it can deliver the microRNA to modulate cellular behavior.

The invention discloses low-temperature injectable hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Hydrogel is prepared from high-molecular-weight hyaluronic acid grafted with vitamin E and poly (N-isopropylacrylamide), the hydrogel is in an injectable liquid state at 4 DEG C, and a drug capsaicin (CPZ) wrapped by micelle is loaded and injected into the brain from the brain in a stereotactic mode. The pharmaceutical composition can temporarily maintain local low temperature of brain tissue and release capsaicin, reduce local metabolic activity of ischemic brain tissue, temporarily inhibit biogenesis, reduce NADH, FADH2 and other reducing equivalents and ADP accumulation, reduce the possibility of electron leakage in an electron transport chain, and improve the bioavailability of ischemic brain tissue. Vitamin E is added to reduce superoxide anions (O2 <.->) generated by reduction reaction of oxygen and leaked electrons in the reperfusion process, and vitamin E can promote ROS removal, synergistically alleviate oxidative stress and subsequent inflammation, and comprehensively improve cerebral ischemia reperfusion injury.

The invention discloses application of a bombyx mori key gene circ0000157, and belongs to the field of biotechnology research. By analyzing the biogenesis mechanism of the circ0000157, it is proved that the circ0000157 is formed by reverse shearing of an exon and an intron. The circularity of circRNA is verified through agarose gel electrophoresis, Sanger sequencing and exonuclease digestion, it is verified through experiments that proliferation of the nosema bombycis can be inhibited by inhibiting expression of the key gene circ0000157 of the nosema bombycis in a host, and it is proved that the circ0000157 serves as a molecular sponge to adjust the miR-281-5p to affect proliferation of the nosema bombycis. A foundation is laid for analysis of an infection mechanism of the nosema bombycis, and an important target is provided for creation of resistance materials.

The application provides a fungal tangeretin derivative tangeretin A, and a structural formula of the compound is The tangeretin A provided by the application is a tangeretin derivative with a novel skeleton structure, is a tetraloop novel skeleton type, has a rare spiro skeleton, is a polymer formed by a quinone tangeretin and 2-hexene 1,3-diene-2,5-dimethyl furanone in terms of biogenesis, and can be applied to preparation of human pathogenic bacteria and an agricultural antibiotic precursor, and lays a material foundation for next-step biological medicine and pesticide research and application of an antibacterial component.

The invention discloses a strain of Bifidobacterium longum subspecies longum for lowering blood pressure and blood lipids, and its postbiotics and applications, and relates to the technical field of microbial fermentation. The invention screens and obtains a strain of Bifidobacterium longum subspecies longum ( Bifidobacterium longum subsp. long )WZA‑BL01, which has a deposit number of: CCTCC NO: M 20241531. The long subspecies of Bifidobacterium longum is obtained by fermenting and culturing the long subspecies of Bifidobacterium longum, and the long subspecies of Bifidobacterium longum postbiotics are combined with natto extract and mulberry leaf extract to prepare a blood pressure and blood lipid lowering product. The product can significantly reduce the tail vein pressure and the content of total cholesterol, triglycerides, and low-density lipoprotein in rats, and increase the content of high-density lipoprotein. It can be seen that the long subspecies of Bifidobacterium longum and its postbiotics obtained by the present invention can have the dual effects of lowering blood pressure and lowering blood lipids.

The invention discloses an engineered extracellular vesicle capable of efficiently delivering circular RNA (Ribonucleic Acid) based on an intracellular cyclization technology as well as a construction method and application of the engineered extracellular vesicle. A circRNA expression vector is designed on the basis of a tRNA shearing mediated cyclization mechanism, and the sequence of the circRNA expression vector is systematically optimized, so that the transcription and translation efficiency in mammalian cells is improved. Secondly, the EV membrane is subjected to engineering modification by displaying an RNA binding protein capable of recognizing and enriching circRNA. Thirdly, biogenesis and secretion of the EV are enhanced by co-expressing the key regulatory gene. By integrating these methods, a robust platform is established for high-yield encapsulation and functional delivery of circRNA, and has been verified by in vivo studies. In a word, the work provides an extensible and efficient engineering framework for circRNA treatment based on EV, and opens up a new way for RNA delivery.

Described are microfluidic high-throughput single cell transwell systems for culturing single paired cells for real time monitoring of exosomes biogenesis, transportation and internalization between paired single cells.

A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV / alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces. Vaccination with multiantigenic self-adjuvanting bionanoparticles from Pseudomonas was also successfully tested in connection with Pseudomonas aeruginosa.

Unlike DNA, mRNA has the advantage that transient expression of the desired protein can be achieved directly in the cytoplasm without entry into the nucleus, so that the attempt of mRNA vaccines is being positively performed. However, the structural stability of mRNA is lower than that of DNA, so that the mRNA has certain limitation in the aspect of industrial application. Therefore, the present invention relates to a technique for significantly improving intracellular stability and biosynthesis of mRNA. The mRNA stabilization method and the mRNA stabilization composition according to the present invention have excellent effects of enhancing the stability of a target nucleic acid and the expression of a target protein in mRNA vaccines and the like, and thus are expected to be widely used in the health / medical field.

The invention discloses a preparation process and application of a bifidobacterium longum HSBL001 metagen and a compounded metagen, and relates to the technical field of microorganisms. The invention provides a bifidobacterium longum HSBL001, and the preservation number of the bifidobacterium longum HSBL001 is CGMCC (China General Microbiological Culture Collection Center) No.31244. The invention also provides a preparation method of the bifidobacterium longum HSBL001. The invention also provides a fermentation medium of the bifidobacterium longum, and the preparation method comprises the following steps: dissolving the skimmed milk powder and the soybean powder or the skimmed milk powder and the soybean protein isolate, adding the papain for enzymolysis, and adding the pH regulator after enzyme deactivation and sterilization to obtain the fermentation medium. The culture medium can increase the fermentation viable count of the bifidobacterium longum, and the bifidobacterium longum metagen and the bifidobacterium longum compound metagen prepared by using the culture medium have the effect of relieving colitis.

The present invention provides methods for diagnosing or predicting fertility defects, such as infertility, in a mammalian male subject by detecting CCDC175. The invention also provides kits and instruments for diagnosing or predicting fertility defects, such as infertility disorders, in mammalian male individuals by detecting CCDC175. The invention finds and proves for the first time that deletion of CCDC175 destroys acrosome biogenesis of mammal sperms, resulting in serious spermatogenesis arrest and enhanced spermatogenic cell apoptosis, thereby providing a method for diagnosing infertility of mammals, including humans. And a new thought and a new method are provided for treatment of male sterility individuals influenced by gene mutation.

This disclosure relates to methods, kits and cell lines for retrieving potent RNAi triggers sequences, by utilizing a cell population having an altered RNAi biogenesis machinery, expressing in the cell population nucleic acid constructs, encoding a candidate RNAi trigger targeting a target gene, selecting cells expressing the target gene, rescuing the genetic alteration in the RNAi machinery, and identifying cells expressing a potent RNAi trigger by identifying cells which no longer express the target gene or which express only low levels of the target gene, as compared to the expression level of the target gene prior to rescuing procedure.

Described herein are systems, compositions, methods, and kits relating to the study and inhibition of ecDNA formation. Described herein are reporter systems useful for identifying intracellular molecular regulators of ecDNA formation. Described herein are reporter systems that are useful as screens for identifying inhibitors of ecDNA formation. Also described herein are methods relating to further identifying molecular mechanisms of ecDNA biogenesis. Also described herein are methods of treating a disease in a subject by an administering an agent that inhibits ecDNA formation.

The present invention provides the use of a TRPML1-specific small molecule agonist ML-SA1 in the pharmaceutical industry. Through single and multiple uranium exposures to simulate acute and chronic uranium-exposed mouse models, it was confirmed that delayed administration of the small molecule compound ML-SA1 can significantly promote the urinary uranium excretion of acute and chronic uranium-exposed mice, reduce renal uranium accumulation, alleviate the pathological damage and apoptosis of uranium-induced renal proximal tubular epithelial cells, protect renal function, and is closely related to the significant improvement of lysosomal exocytosis; through the uranium-exposed human renal proximal tubular epithelial HK-2 cell model, it was confirmed that delayed administration of the small molecule compound ML-SA1 significantly promotes the excretion of uranium accumulated in HK-2 cells by promoting lysosomal exocytosis and accompanying compensatory lysosomal biogenesis, and significantly reduces uranium-induced cell death. Since the small molecule compound ML-SA1 excretes uranium deposited in lysosomes out of the cell through lysosomal exocytosis, thereby effectively reducing the intracellular uranium content, it can also be used for the enhanced excretion and detoxification of other heavy metal poisonings deposited in lysosomes.

Unlike DNA, mRNA has the advantage of enabling transient expression of a desired protein directly in the cytoplasm without having to enter the nucleus, and thus attempts to use mRNA vaccines are actively underway. However, mRNA has lower structural stability than DNA, and thus has limitations with respect to industrial application. Therefore, the present invention relates to a technology for remarkably improving intracellular stability and biogenesis of mRNA. An mRNA stabilization method and an mRNA stabilization composition, of the present invention, have the excellent effects of enhancing target nucleic acid stabilization and target protein expression in mRNA vaccines and the like, and thus are expected to be widely used in the health / medical field.

The invention discloses a peanut oil content character related gene AhPEX10 as well as a molecular marker and application thereof, and belongs to the technical field of molecular biology. According to the present invention, the gene AhPEX10 encoded by the peroxisome biogenic factor (Peroxisome biogenic factor 10) associated with the oil content character of the peanut seed is excavated through the GWAS positioning analysis, and the cDNA sequence of the gene is represented by SEQ ID NO: 1; the expression of the gene is in positive correlation with the oil content of peanuts, and the oil content of peanut seeds can be remarkably reduced by silencing the expression of the AhPEX10 gene in the peanuts through a vigs technology. The research finds that the gene AhPEX10 coded by the peroxisome biogenic factor in the peanut can regulate and control the oil content of seeds, and the gene can be used for identifying, screening, cultivating or improving high-oil-content peanut varieties.

This invention discloses a cultivation experimental device suitable for studying the biogenesis mechanism of maize rRNA, belonging to the field of cultivation experimental technology for the biogenesis mechanism of maize rRNA. It includes an experimental platform with a refrigerator at its bottom. A connecting plate is located on one side of the refrigerator, and a cultivation experimental chamber is located on the side of the connecting plate away from the refrigerator. The cultivation experimental chamber has a cultivation tank inside, and a first rotating shaft is rotatably connected to one side of the cultivation tank. This invention, through a series of structural features, creates a dynamic cultivation environment by rotating the platform, precisely matching molecular events and significantly improving the scientific rigor of experimental data. Secondly, it employs a closed-loop precision liquid injection system, allowing for the addition of culture medium without removing the dish, thus improving operational efficiency and avoiding the impact of environmental fluctuations on cell state, ensuring experimental stability and consistency.

The present disclosure provides compositions and methods for increasing mitochondrial function. The present disclosure further provides nanomaterial structures comprising high atomic vacancy concentrations which are used to stimulate mitochondrial production. The resulting mitochondria may be used for mitochondrial transplantation to treat diseases or disorders associated with decreased mitochondrial function.